News

Bevacizumab Halves Progression Risk in Recurrent Ovarian Cancer

Publish date: June 5, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Aghajanian reported being a consultant to and receiving research funding from Genentech, manufacturer of bevacizumab, and the trial was sponsored by Genentech. Dr. Seidman reported being a consultant to Enzon and Wyeth; receiving honoraria from Abraxis BioScience, Genentech, and Genomic Health; and receiving research funding from Abraxis BioScience.

Pages

Recommended Reading

PIVOT Trial: No Overall Benefit to Radical Prostatectomy for Localized Prostate Cancer
MDedge Hematology and Oncology
Two Studies Find Beta-Blockers Help Combat Breast Cancer Progression
MDedge Hematology and Oncology
Adjuvant Chemotherapy Delay Worsens Survival After Colorectal Surgery
MDedge Hematology and Oncology
Video Report: The 2011 ASCO Annual Meeting Kicks Off in Chicago
MDedge Hematology and Oncology
Higher Methotrexate Dose Fends Off Pediatric Leukemia Recurrence
MDedge Hematology and Oncology
Therapy Matched to Tumor Abnormalities Tied to Longer Survival
MDedge Hematology and Oncology
HPV-Related Oral Cancer Incidence Spikes Sharply
MDedge Hematology and Oncology
Exemestane Prevents 65% of Invasive Breast Cancers in Postmenopausal Women
MDedge Hematology and Oncology
Crizotinib Continues to Produce High Response in ALK+ NSCLC
MDedge Hematology and Oncology
Screening Does Not Reduce Ovarian Cancer Mortality
MDedge Hematology and Oncology

Related Articles